Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening
- PMID: 22961208
- PMCID: PMC11824615
- DOI: 10.1007/s00432-012-1304-1
Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening
Abstract
Introduction: In a population-based screening program, a percentage of tumors remain undetected; these tumors comprise a heterogeneous group, and they are more likely to have adverse prognostic features. The aim of this study was to identify differences in biological characteristics of screen-detected versus interval breast cancers in a population-based screening program according to molecular subtypes.
Materials and methods: We analyzed the population-based data from a long-running screening program in the area of Florence. Data on screening history and on age, T and N status, grade, histotype, hormonal status and Ki-67 and HER2 expression were retrieved. Subtypes of breast cancer were defined on the expression of ER, PR, Ki-67 and HER2: luminal A if ER/PR+, HER2- and Ki67 <14 %, luminal B (HER2 negative) if ER/PR+, HER2- and Ki67 ≥14 %, luminal B (HER2 positive) if ER/PR+ and HER2+, triple negative if ER/PR-and HER2-, HER2 positive if ER/PR- and HER2+. Association between molecular subtypes and mode of detection will be evaluated by a logistic regression model adjusted for the potential confounding variables.
Results: Information about biomarkers was known for 277 cases, 211 screening-detected and 66 interval cancers. Among interval cases, the triple-negative cancers were more represented than luminal A (OR = 3.52; CI, 1.112-11.13; p = 0.0319), while the proportion of HER2+ was quite similar (OR = 1.57; p = 0.4709).
Conclusion: Although made on a small number of cases, our results suggest a difference in distribution of molecular subtypes according to mode detection, confirming the results of earlier studies.
Similar articles
-
The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.Breast J. 2023 Nov 11;2023:7028189. doi: 10.1155/2023/7028189. eCollection 2023. Breast J. 2023. PMID: 38021219 Free PMC article.
-
Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.J Cancer Res Clin Oncol. 2018 Sep;144(9):1769-1775. doi: 10.1007/s00432-018-2687-4. Epub 2018 Jun 16. J Cancer Res Clin Oncol. 2018. PMID: 29909564 Free PMC article.
-
Prognostic role of progesterone receptor expression in a population-based analysis.J Cancer Res Clin Oncol. 2017 Dec;143(12):2505-2509. doi: 10.1007/s00432-017-2514-3. Epub 2017 Sep 9. J Cancer Res Clin Oncol. 2017. PMID: 28889189 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.Breast Cancer Res Treat. 2012 Jun;133(3):831-41. doi: 10.1007/s10549-011-1891-6. Epub 2011 Dec 7. Breast Cancer Res Treat. 2012. PMID: 22147079
Cited by
-
Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016.Radiology. 2021 Aug;300(2):290-300. doi: 10.1148/radiol.2021204581. Epub 2021 May 18. Radiology. 2021. PMID: 34003059 Free PMC article.
-
Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort study.Breast Cancer Res. 2018 Aug 9;20(1):95. doi: 10.1186/s13058-018-1025-8. Breast Cancer Res. 2018. PMID: 30092817 Free PMC article.
-
Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.J Clin Oncol. 2018 Jul 10;36(20):2070-2077. doi: 10.1200/JCO.2017.76.8267. Epub 2018 May 2. J Clin Oncol. 2018. PMID: 29718790 Free PMC article.
-
ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer.Oncotarget. 2016 Mar 29;7(13):15811-27. doi: 10.18632/oncotarget.7515. Oncotarget. 2016. PMID: 26908458 Free PMC article.
-
Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study.Curr Breast Cancer Rep. 2020 Sep;12(3):149-160. doi: 10.1007/s12609-020-00365-0. Epub 2020 May 14. Curr Breast Cancer Rep. 2020. PMID: 33815665 Free PMC article.
References
-
- Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M (2003) Her-2/Neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 23(5b):4213–4218 - PubMed
-
- Bernstein L, Lacey JV Jr (2011) Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative? JNCI 103(6):2–4 - PubMed
-
- Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17(3):753–758 - PubMed
-
- Collett K, Stefansonn IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA (2005) A basal epithelial phenotype is more frequent in interval breast cancer compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108–1112 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous